Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook

Rhea-AI Summary

Abbott (NYSE: ABT) reported fourth-quarter 2025 and full-year results and issued 2026 guidance. 4Q25 GAAP diluted EPS $1.01; adjusted diluted EPS $1.50 (+12%). Full-year 2025 GAAP diluted EPS $3.72; adjusted diluted EPS $5.15 (+10%). Full-year 2025 sales were $44.3 billion (+5.7% reported; +5.5% organic). Abbott projects 2026 organic sales +6.5% to +7.5% and adjusted diluted EPS $5.55–$5.80 (midpoint ≈ +10%). Company expects Exact Sciences acquisition to close in Q2 2026 and noted FDA approval for the Volt PFA System and CE Mark for TactiFlex Duo.

Positive

• Adjusted EPS +10% for full-year 2025
• Full-year sales $44.3B (+5.7% reported)
• 2026 guidance: organic sales +6.5%–7.5%
• Medical Devices: Sales +12.3% in 4Q25 (reported)
• Diabetes Care sales $2.0B in 4Q25 (+15.0%)
• Regulatory: FDA approval for Volt PFA System

Negative

• Nutrition sales -8.9% in 4Q25 (reported)
• Diagnostics sales -2.5% in 4Q25 (reported)
• Full-year Diagnostics -4.3% reported in 2025
• 4Q25 GAAP diluted EPS $1.01 (below adjusted EPS)

News Market Reaction

-10.04%

45 alerts

-10.04% News Effect

-8.2% Trough in 1 hr 58 min

-$23.43B Valuation Impact

$209.93B Market Cap

0.4x Rel. Volume

On the day this news was published, ABT declined 10.04%, reflecting a significant negative market reaction. Argus tracked a trough of -8.2% from its starting point during tracking. Our momentum scanner triggered 45 alerts that day, indicating elevated trading interest and price volatility. This price movement removed approximately $23.43B from the company's valuation, bringing the market cap to $209.93B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Q4 2025 GAAP EPS: $1.01 Q4 2025 adj EPS: $1.50 FY 2025 sales: $44.3B +5 more

8 metrics

Q4 2025 GAAP EPS $1.01 Fourth-quarter 2025 GAAP diluted EPS

Q4 2025 adj EPS $1.50 Fourth-quarter 2025 adjusted diluted EPS, 12% growth

FY 2025 sales $44.3B Full-year 2025 sales, 5.7% reported growth

FY 2025 adj EPS $5.15 Full-year 2025 adjusted diluted EPS, 10% growth

2026 organic growth guide 6.5%–7.5% Projected full-year 2026 organic sales growth range

2026 EPS guidance $5.55–$5.80 Projected 2026 adjusted diluted EPS, 10% growth at midpoint

CGM sales $2.0B Diabetes Care continuous glucose monitor sales in 2025, 15.0% growth

Quarterly dividend $0.63/share 408th consecutive quarterly dividend; 54 years of increases

Market Reality Check

Price: $107.42 Vol: Volume 12,338,742 is 1.97...

high vol

$107.42 Last Close

Volume Volume 12,338,742 is 1.97x the 20-day average of 6,248,387 shares, indicating elevated trading interest. high

Technical ABT trades at $120.73, below its 200-day MA of $129.77 and 14.52% under the 52-week high of $141.23.

Peers on Argus

Ahead of these results, ABT was modestly lower (-0.34%) while key device peers l...

Ahead of these results, ABT was modestly lower (-0.34%) while key device peers like SYK, MDT, and EW showed small gains and SNN edged lower. Moves across peers were mixed and small, suggesting no clear sector-wide driver.

Historical Context

5 past events · Latest: Jan 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 20	EP device CE Mark	Positive	-0.5%	CE Mark for TactiFlex Duo AFib ablation catheter enabling EU commercialization.
Jan 05	Earnings call notice	Neutral	+1.1%	Announcement of date and time for Q4 2025 earnings release and webcast.
Jan 05	Diabetes app launch	Positive	+1.8%	Launch of Libre Assist AI feature to guide food decisions for diabetes patients.
Dec 22	Volt PFA FDA OK	Positive	-0.2%	FDA approval of Volt PFA System for treating atrial fibrillation based on VOLT-AF study.
Dec 18	Piccolo system clearances	Positive	-1.3%	FDA clearance and CE Mark for Amplatzer Piccolo delivery system for premature infants with PDA.

Pattern Detected

Recent history shows 3 positive clinical/regulatory catalysts followed by slight share price declines, while digital/consumer-focused launches and neutral events saw modest gains, indicating occasional sell-the-news behavior on approvals.

Recent Company History

Over the last few months, Abbott reported multiple cardiovascular and structural heart milestones, including FDA approval of the Volt™ PFA System and dual FDA/CE Mark clearance for the Amplatzer Piccolo delivery system (Dec 2025). It also advanced electrophysiology with CE Mark for the TactiFlex™ Duo catheter (Jan 20, 2026) and expanded its diabetes ecosystem via the Libre Assist AI feature (Jan 5, 2026). Those product wins sometimes saw muted or negative price reactions, framing today’s broad earnings and guidance update against a backdrop of strong but often underrewarded innovation.

Market Pulse Summary

The stock dropped -10.0% in the session following this news. A negative reaction despite solid 2025 ...

Analysis

The stock dropped -10.0% in the session following this news. A negative reaction despite solid 2025 EPS growth and 2026 guidance would fit past patterns where positive device and regulatory news, such as Volt™ PFA and Amplatzer Piccolo clearances, preceded slight declines. Investors may have focused on weaker segments like Nutrition or lingering COVID-19 testing headwinds. With ABT trading below its 200-day MA of $129.77, any sharp drop could reflect pre-existing technical pressure rather than just this earnings release.

Key Terms

gaap, organic sales growth, u.s. food and drug administration (fda), ce mark, +4 more

8 terms

gaap financial

"Fourth-quarter GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.50..."

GAAP, or Generally Accepted Accounting Principles, are a set of standardized rules and guidelines that companies follow when preparing their financial statements. They ensure consistency, transparency, and comparability across different companies, making it easier for investors to understand and compare financial information accurately. This helps investors make informed decisions based on trustworthy and uniform financial reports.

organic sales growth financial

"Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%."

Organic sales growth measures how much a company’s revenue rises from its regular business activity — like selling more products, charging higher prices, or selling to more customers — without counting money from buying other businesses or one-time currency effects. Investors watch it because it shows whether demand and the company’s core operations are genuinely getting stronger, similar to judging a garden by how much the plants you planted yourself are growing rather than by adding bought potted plants.

u.s. food and drug administration (fda) regulatory

"Abbott announced U.S. Food and Drug Administration (FDA) approval for its Volt™ PFA System..."

The U.S. Food and Drug Administration (FDA) is a government agency responsible for protecting public health by ensuring the safety and effectiveness of food, medicines, vaccines, and other health-related products. For investors, the FDA’s decisions can significantly impact companies in the healthcare and food industries, as approval or rejection of products can influence a company's success and stock performance.

ce mark regulatory

"Abbott announced the company obtained CE Mark for its TactiFlex™ Duo Ablation Catheter..."

A CE mark is a regulatory stamp placed on products to show they meet the European Union’s basic safety, health and environmental rules and can be sold in the European Economic Area. For investors it matters because the mark unlocks market access, affects how quickly a product can generate revenue, and signals regulatory risk and potential compliance costs—think of it as a passport that lets a product enter a large market.

pulsed field ablation (pfa) medical

"bringing Abbott's first pulsed field ablation (PFA) offering to patients..."

Pulsed field ablation (PFA) is a medical procedure that uses short, high-voltage electric pulses to selectively disable small areas of heart tissue that cause abnormal rhythms, effectively creating tiny barriers that stop errant electrical signals. For investors, PFA matters because it represents a new approach to treating heart rhythm disorders with potential advantages in speed, precision and safety over older methods, which can affect device sales, regulatory approvals and adoption by hospitals and clinicians.

atrial fibrillation medical

"designed to deliver radiofrequency (RF) and PFA energy to treat patients battling atrial fibrillation."

Atrial fibrillation is a common heart rhythm problem in which the heart’s upper chambers quiver instead of delivering steady, strong pumps, like a washing machine on an unbalanced cycle. It matters to investors because it increases use of medications, medical devices, hospital care and long‑term monitoring, drives demand for new treatments and diagnostics, and can affect healthcare costs, regulatory decisions and revenue prospects across drug, device and insurance markets.

continuous glucose monitors medical

"In Diabetes Care, sales of continuous glucose monitors were $2.0 billion..."

A continuous glucose monitor is a small wearable device with a sensor placed just under the skin that measures blood-sugar levels around the clock and sends those readings to a display or smartphone — like a fitness tracker for glucose. Investors care because adoption and repeat purchases of sensors and supplies create steady revenue, while clinical usefulness, pricing, insurance coverage and regulatory approval determine how fast and widely the devices sell.

dividend aristocrats index financial

"member of the S&P 500 Dividend Aristocrats Index, which tracks companies..."

A dividend aristocrats index is a benchmark made up of publicly traded companies that have a long, continuous record of raising their dividend payments year after year. Think of it as a curated list of steady income growers; investors use it like a shopping list for more reliable dividends, a way to measure income-focused performance, and a lower-volatility alternative when comparing stocks or building portfolios.

AI-generated analysis. Not financial advice.

• Fourth-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.50 reflects growth of 12 percent
• Full-year 2025 GAAP diluted EPS of $3.72; adjusted diluted EPS of $5.15 reflects growth of 10 percent
• Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%
• Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects 10 percent growth at the midpoint

ABBOTT PARK, Ill., Jan. 22, 2026 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2025.

• Fourth-quarter sales increased 4.4 percent on a reported basis, 3.0 percent on an organic basis, or 3.8 percent when excluding COVID-19 testing-related sales¹.
• Fourth-quarter GAAP diluted EPS of $1.01 and adjusted diluted EPS of $1.50, which excludes specified items and reflects growth of 12 percent.
• Full-year 2025 sales of $44.3 billion increased 5.7 percent on a reported basis, 5.5 percent on an organic basis, or 6.7 percent when excluding COVID-19 testing-related sales².
• Full-year 2025 GAAP diluted EPS of $3.72 and adjusted diluted EPS of $5.15, which excludes specified items and reflects growth of 10 percent.
• Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%.
• Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects growth of 10 percent at the midpoint.
• In November, Abbott announced an agreement to acquire Exact Sciences, a move that will position the company to enter and lead in the fast-growing cancer diagnostics market. Abbott continues to expect the transaction to close in the second quarter of 2026.
• Abbott expanded its leadership in Electrophysiology with two significant regulatory approvals:
  • In December, Abbott announced U.S. Food and Drug Administration (FDA) approval for its Volt™ PFA System, bringing Abbott's first pulsed field ablation (PFA) offering to patients in the United States.
  • In January, Abbott announced the company obtained CE Mark for its TactiFlex™ Duo Ablation Catheter, Sensor Enabled™, designed to deliver radiofrequency (RF) and PFA energy to treat patients battling atrial fibrillation.

"In 2025, we expanded margins and achieved double-digit earnings per share growth, our new product pipeline was highly productive, and we took important strategic steps to shape the company for the future," said Robert B. Ford, chairman and chief executive officer, Abbott. "We're well positioned for accelerating growth in 2026."

FOURTH-QUARTER BUSINESS OVERVIEW

Management believes that measuring sales growth rates on an organic basis, which excludes the impact of foreign exchange and the impact of discontinuing the ZonePerfect^® product line in the Nutrition business, is an appropriate way for investors to best understand the core underlying performance of the business. Management further believes that measuring sales growth rates on an organic basis excluding COVID-19 tests is an appropriate way for investors to best understand the underlying performance of the company as the demand for COVID-19 tests has significantly declined following the transition from a pandemic to endemic phase.

Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.  

Fourth Quarter 2025 Results (4Q25)
Sales 4Q25 ($ in millions)	Total Company		Nutrition		Diagnostics		Established Pharmaceuticals		Medical Devices
U.S.	4,383		806		967		—		2,605
International	7,076		1,134		1,490		1,382		3,070
Total reported	11,459		1,940		2,457		1,382		5,675
% Change vs. 4Q24
U.S.	0.9		(13.2)		(8.4)		n/a		10.7
International	6.7		(5.6)		1.8		9.0		13.7
Total reported	4.4		(8.9)		(2.5)		9.0		12.3
Impact of foreign exchange	1.4		0.2		1.1		2.0		1.9
Organic	3.0		(9.1)		(3.6)		7.0		10.4
Impact of COVID-19 testing sales 1	(0.8)		—		(3.4)		—		—
Organic (excluding COVID-19 tests)	3.8		(9.1)		(0.2)		7.0		10.4
Organic
U.S.	0.9		(13.2)		(8.4)		n/a		10.7
International	4.3		(5.9)		(0.2)		7.0		10.1

 

Full-Year 2025 Results (12M25)
Sales 12M25 ($ in millions)	Total Company		Nutrition		Diagnostics		Established Pharmaceuticals		Medical Devices
U.S.	17,126		3,606		3,535		—		9,968
International	27,202		4,845		5,402		5,536		11,419
Total reported	44,328		8,451		8,937		5,536		21,387
% Change vs. 12M24
U.S.	4.9		(2.3)		(7.7)		n/a		13.4
International	6.1		2.6		(2.0)		6.6		12.0
Total reported	5.7		0.4		(4.3)		6.6		12.6
Impact of foreign exchange	0.2		(0.7)		0.2		(0.8)		0.7
Impact of business exit*	—		(0.1)		—		—		—
Organic	5.5		1.2		(4.5)		7.4		11.9
Impact of COVID-19 testing sales 2	(1.2)		—		(4.9)		—		—
Organic (excluding COVID-19 tests)	6.7		1.2		0.4		7.4		11.9
Organic
U.S.	5.0		(1.9)		(7.7)		n/a		13.4
International	5.9		3.7		(2.3)		7.4		10.5

Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue.

*Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024.

 

Nutrition
Fourth Quarter 2025 Results (4Q25)
Sales 4Q25 ($ in millions)	Total		Pediatric		Adult
U.S.	806		463		343
International	1,134		439		695
Total reported	1,940		902		1,038
% Change vs. 4Q24
U.S.	(13.2)		(17.7)		(6.3)
International	(5.6)		0.3		(8.9)
Total reported	(8.9)		(9.8)		(8.1)
Impact of foreign exchange	0.2		0.3		0.1
Organic	(9.1)		(10.1)		(8.2)
U.S.	(13.2)		(17.7)		(6.3)
International	(5.9)		(0.3)		(9.1)

Worldwide Nutrition sales decreased 8.9 percent on a reported basis and 9.1 percent on an organic basis in the fourth quarter.

Results in the quarter reflect the impact of lower sales volumes compared to the prior year and new strategic price actions targeted to increase volume growth in the future. In addition to these strategic price actions, Abbott expects to increase volume growth with the launch of several new products in 2026. 

Full-Year 2025 Results (12M25)
Sales 12M25 ($ in millions)	Total		Pediatric		Adult
U.S.	3,606		2,158		1,448
International	4,845		1,816		3,029
Total reported	8,451		3,974		4,477
% Change vs. 12M24
U.S.	(2.3)		(2.3)		(2.2)
International	2.6		0.1		4.1
Total reported	0.4		(1.2)		2.0
Impact of foreign exchange	(0.7)		(0.5)		(0.7)
Impact of business exit*	(0.1)		—		(0.3)
Organic	1.2		(0.7)		3.0
U.S.	(1.9)		(2.3)		(1.4)
International	3.7		1.3		5.1

*Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business in March 2024.

 

Diagnostics
Fourth Quarter 2025 Results (4Q25)
Sales 4Q25 ($ in millions)	Total		Core Laboratory		Molecular		Point of Care		Rapid Diagnostics
U.S.	967		376		39		107		445
International	1,490		1,085		102		51		252
Total reported	2,457		1,461		141		158		697
% Change vs. 4Q24
U.S.	(8.4)		3.6		2.9		6.5		(19.7)
International	1.8		5.9		3.3		9.8		(14.1)
Total reported	(2.5)		5.3		3.2		7.5		(17.8)
Impact of foreign exchange	1.1		1.7		2.1		0.4		0.3
Organic	(3.6)		3.6		1.1		7.1		(18.1)
U.S.	(8.4)		3.6		2.9		6.5		(19.7)
International	(0.2)		3.6		0.4		8.3		(14.9)

Global Diagnostics sales decreased 2.5 percent on a reported basis, decreased 3.6 percent on an organic basis, and decreased 0.2 percent when excluding COVID-19 testing-related sales¹.

COVID-19 testing-related sales were $89 million in the quarter, compared to $176 million in the fourth quarter of the prior year.

Global Core Laboratory Diagnostics sales increased 5.3 percent on a reported basis and increased 3.6 percent on an organic basis. Growth in other geographies was partially offset by challenging market conditions in China, including the impact of volume-based procurement programs. 

Full-Year 2025 Results (12M25)
Sales 12M25 ($ in millions)	Total		Core Laboratory		Molecular		Point of Care		Rapid Diagnostics
U.S.	3,535		1,425		150		422		1,538
International	5,402		3,935		367		184		916
Total reported	8,937		5,360		517		606		2,454
% Change vs. 12M24
U.S.	(7.7)		7.0		0.4		3.4		(20.8)
International	(2.0)		0.8		(1.1)		2.5		(13.3)
Total reported	(4.3)		2.4		(0.7)		3.1		(18.1)
Impact of foreign exchange	0.2		0.3		0.5		—		(0.1)
Organic	(4.5)		2.1		(1.2)		3.1		(18.0)
U.S.	(7.7)		7.0		0.4		3.4		(20.8)
International	(2.3)		0.4		(1.8)		2.4		(13.1)

 

Established Pharmaceuticals
Fourth Quarter 2025 Results (4Q25)
Sales 4Q25 ($ in millions)	Total		Key Emerging Markets		Other
U.S.	—		—		—
International	1,382		1,046		336
Total reported	1,382		1,046		336
% Change vs. 4Q24
U.S.	n/a		n/a		n/a
International	9.0		10.3		5.0
Total reported	9.0		10.3		5.0
Impact of foreign exchange	2.0		1.6		3.1
Organic	7.0		8.7		1.9
U.S.	n/a		n/a		n/a
International	7.0		8.7		1.9

Established Pharmaceuticals sales increased 9.0 percent on a reported basis and 7.0 percent on an organic basis in the fourth quarter.

Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott's branded generics product portfolio. Sales in these geographies increased 10.3 percent on a reported basis and 8.7 percent on an organic basis, led by double-digit growth in India and several countries across Latin America and the Middle East.

Full-Year 2025 Results (12M25)
Sales 12M25 ($ in millions)	Total		Key Emerging Markets		Other
U.S.	—		—		—
International	5,536		4,167		1,369
Total reported	5,536		4,167		1,369
% Change vs. 12M24
U.S.	n/a		n/a		n/a
International	6.6		8.0		2.5
Total reported	6.6		8.0		2.5
Impact of foreign exchange	(0.8)		(1.5)		1.1
Organic	7.4		9.5		1.4
U.S.	n/a		n/a		n/a
International	7.4		9.5		1.4

 

Medical Devices
Fourth Quarter 2025 Results (4Q25)
Sales 4Q25 ($ in millions)	Total		Rhythm Management		Electro- physiology		Heart Failure		Vascular		Structural Heart		Neuro- modulation		Diabetes Care
U.S.	2,605		340		340		283		287		304		208		843
International	3,070		365		390		92		496		371		66		1,290
Total reported	5,675		705		730		375		783		675		274		2,133
% Change vs. 4Q24
U.S.	10.7		12.8		13.1		11.7		6.5		4.8		1.9		14.9
International	13.7		13.4		13.9		17.9		8.9		16.3		23.8		14.2
Total reported	12.3		13.1		13.5		13.2		8.0		10.8		6.5		14.5
Impact of foreign exchange	1.9		1.6		1.0		1.1		1.5		2.1		0.9		2.8
Organic	10.4		11.5		12.5		12.1		6.5		8.7		5.6		11.7
U.S.	10.7		12.8		13.1		11.7		6.5		4.8		1.9		14.9
International	10.1		10.2		11.9		13.4		6.6		12.3		19.6		9.6

Worldwide Medical Devices sales increased 12.3 percent on a reported basis and 10.4 percent on an organic basis in the fourth quarter.

Sales growth in the quarter was led by double-digit growth in Electrophysiology, Heart Failure, Diabetes Care, and Rhythm Management.

In Diabetes Care, sales of continuous glucose monitors were $2.0 billion and grew 15.0 percent on a reported basis and 12.2 percent on an organic basis. 

Full-Year 2025 Results (12M25)
Sales 12M25 ($ in millions)	Total		Rhythm Management		Electro- physiology		Heart Failure		Vascular		Structural Heart		Neuro- modulation		Diabetes Care
U.S.	9,968		1,334		1,283		1,107		1,118		1,172		773		3,181
International	11,419		1,315		1,481		341		1,877		1,351		237		4,817
Total reported	21,387		2,649		2,764		1,448		2,995		2,523		1,010		7,998
% Change vs. 12M24
U.S.	13.4		15.7		12.4		12.2		5.8		11.5		0.8		20.8
International	12.0		6.4		11.7		16.4		5.4		13.0		21.5		15.4
Total reported	12.6		10.9		12.0		13.2		5.6		12.3		5.0		17.5
Impact of foreign exchange	0.7		0.7		0.4		0.5		0.5		0.8		0.2		1.2
Organic	11.9		10.2		11.6		12.7		5.1		11.5		4.8		16.3
U.S.	13.4		15.7		12.4		12.2		5.8		11.5		0.8		20.8
International	10.5		5.0		10.9		14.3		4.7		11.5		20.5		13.5

ABBOTT'S FINANCIAL GUIDANCE
Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%.

Abbott projects full-year 2026 adjusted diluted earnings per share of $5.55 to $5.80 and first-quarter 2026 adjusted diluted earnings per share of $1.12 to $1.18.

Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP.

ABBOTT DECLARES 408^th CONSECUTIVE QUARTERLY DIVIDEND
On Dec. 12, 2025, the board of directors of Abbott declared the company's quarterly dividend of $0.63 per share. Abbott's cash dividend is payable Feb. 13, 2026, to shareholders of record at the close of business on Jan. 15, 2026.

Abbott has increased its dividend payout for 54 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.

About Abbott:
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 115,000 colleagues serve people in more than 160 countries.

Connect with us at www.abbott.com and on LinkedIn, Facebook, Instagram, X and YouTube. 

Abbott will live-webcast its fourth-quarter earnings conference call through its Investor Relations website at www.abbottinvestor.com at 8 a.m. Central time today. An archived edition of the webcast will be available later in the day.

— Private Securities Litigation Reform Act of 1995 —
A Caution Concerning Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Economic, competitive, governmental, technological and other factors that may affect Abbott's operations are discussed in Item 1A, "Risk Factors" in our Annual Report on Form 10-K for the year ended Dec. 31, 2024, and are incorporated herein by reference. Abbott undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

1.	In the fourth quarter of 2025, total worldwide sales were $11.459 billion, total Diagnostics sales were $2.457 billion and COVID-19 testing-related sales were $89 million. In the fourth quarter of 2024, total worldwide sales were $10.974 billion, total Diagnostics sales were $2.520 billion and COVID-19 testing-related sales were $176 million.
2.	In the full-year 2025, total worldwide sales were $44.328 billion, total Diagnostics sales were $8.937 billion and COVID-19 testing-related sales were $297 million. In the full year 2024, total worldwide sales were $41.950 billion, total Diagnostics sales were $9.341 billion and COVID-19 testing-related sales were $747 million.

 

Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings Fourth Quarter Ended December 31, 2025 and 2024 (in millions, except per share data) (unaudited)
	4Q25		4Q24		% Change
Net Sales	$11,459		$10,974		4.4
Cost of products sold, excluding amortization expense	4,922		4,942		(0.4)
Amortization of intangible assets	422		465		(9.4)
Research and development	735		749		(1.9)
Selling, general, and administrative	3,129		2,907		7.7
Total Operating Cost and Expenses	9,208		9,063		1.6
Operating Earnings	2,251		1,911		17.8
Interest expense, net	42		45		(8.0)
Net foreign exchange (gain) loss	(15)		(10)		n/m
Other (income) expense, net	(134)		(154)		(13.0)
Earnings before taxes	2,358		2,030		16.1
Taxes on earnings	582		(7,199)		n/m	1)
Net Earnings	$1,776		$9,229		n/m
Net Earnings excluding Specified Items, as described below	$2,630		$2,349		11.9	2)
Diluted Earnings per Common Share	$1.01		$5.27		n/m
Diluted Earnings per Common Share, excluding Specified Items, as described below	$1.50		$1.34		11.9	2)
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options	1,747		1,746

NOTES:
See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following section.
1)	2025 Taxes on Earnings includes the recognition of approximately $20 million of net tax expense as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $150 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
	2024 Taxes on Earnings includes $7.497 billion in non-cash valuation allowance adjustments resulting from the restructuring of certain foreign affiliates and the confirmation of certain tax filing positions.
2)	2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $854 million, or $0.49 per share, for intangible amortization, charges related to restructuring, legal reserves, acquisitions, and other net expenses.
	2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax benefits of $6.880 billion, or $3.93 per share, for non-cash valuation allowance adjustments, intangible amortization, charges related to intangible impairments, expenses associated with restructuring actions, acquisitions and other net expenses.

 

Abbott Laboratories and Subsidiaries Condensed Consolidated Statement of Earnings Twelve Months Ended December 31, 2025 and 2024 (in millions, except per share data) (unaudited)
	12M25		12M24		% Change
Net Sales	$44,328		$41,950		5.7
Cost of products sold, excluding amortization expense	19,319		18,706		3.3
Amortization of intangible assets	1,682		1,878		(10.5)
Research and development	2,942		2,844		3.5
Selling, general, and administrative	12,332		11,697		5.4
Total Operating Cost and Expenses	36,275		35,125		3.3
Operating Earnings	8,053		6,825		18.0
Interest expense, net	185		215		(13.8)
Net foreign exchange (gain) loss	(50)		(27)		n/m
Other (income) expense, net	(548)		(376)		45.9
Earnings before taxes	8,466		7,013		20.7
Taxes on earnings	1,942		(6,389)		n/m	1)
Net Earnings	$6,524		$13,402		n/m
Net Earnings excluding Specified Items, as described below	$9,040		$8,200		10.2	2)
Diluted Earnings per Common Share	$3.72		$7.64		n/m
Diluted Earnings per Common Share, excluding Specified Items, as described below	$5.15		$4.67		10.3	2)
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options	1,749		1,748

NOTES:
See table titled "Non-GAAP Reconciliation of Financial Information" for an explanation of certain non-GAAP financial information.
n/m = Percent change is not meaningful.
See footnotes on the following section.
1)	2025 Taxes on Earnings includes the recognition of approximately $70 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $610 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
	2024 Taxes on Earnings includes $7.497 billion in non-cash valuation allowance adjustments resulting from the restructuring of certain foreign affiliates and the confirmation of certain tax filing positions.
2)	2025 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax charges of $2.516 billion, or $1.43 per share, for intangible amortization, charges related to investment impairments,  restructuring, legal reserves, acquisitions, and other net expenses.
	2024 Net Earnings and Diluted Earnings per Common Share, excluding Specified Items, excludes net after-tax benefits of $5.202 billion, or $2.97 per share, for non-cash valuation allowance adjustments, intangible amortization, charges related to intangible impairments, expenses associated with restructuring actions, acquisitions and a divestiture, and other net expenses.

 

Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information Fourth Quarter Ended December 31, 2025 and 2024 (in millions, except per share data) (unaudited)
	4Q25
	As Reported (GAAP)		Specified Items		As Adjusted
Intangible Amortization	$          422		$        (422)		$              —
Gross Margin	6,115		428		6,543
R&D	735		(29)		706
SG&A	3,129		(254)		2,875
Other (income) expense, net	(134)		(17)		(151)
Earnings before taxes	2,358		728		3,086
Taxes on Earnings	582		(126)		456
Net Earnings	1,776		854		2,630
Diluted Earnings per Share	$           1.01		$         0.49		$          1.50

Specified items reflect intangible amortization expense of $422 million and other net expenses of $306 million associated with restructuring actions, legal reserves, acquisitions, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

	4Q24
	As Reported (GAAP)		Specified Items		As Adjusted
Intangible Amortization	$          465		$        (465)		$              —
Gross Margin	5,567		673		6,240
R&D	749		(59)		690
SG&A	2,907		(21)		2,886
Other (income) expense, net	(154)		20		(134)
Earnings before taxes	2,030		733		2,763
Taxes on Earnings	(7,199)		7,613		414
Net Earnings	9,229		(6,880)		2,349
Diluted Earnings per Share	$         5.27		$        (3.93)		$          1.34

Specified items reflect intangible amortization expense of $465 million and other net expenses of $268 million associated with restructuring actions, acquisitions and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

Abbott Laboratories and Subsidiaries Non-GAAP Reconciliation of Financial Information Twelve Months Ended December 31, 2025 and 2024 (in millions, except per share data) (unaudited)
	12M25
	As Reported (GAAP)		Specified Items		As Adjusted
Intangible Amortization	$       1,682		$      (1,682)		$              —
Gross Margin	23,327		1,824		25,151
R&D	2,942		(112)		2,830
SG&A	12,332		(312)		12,020
Other (income) expense, net	(548)		(48)		(596)
Earnings before taxes	8,466		2,296		10,762
Taxes on Earnings	1,942		(220)		1,722
Net Earnings	6,524		2,516		9,040
Diluted Earnings per Share	$         3.72		$          1.43		$          5.15

Specified items reflect intangible amortization expense of $1.682 billion and other net expenses of $614 million associated with restructuring actions, legal reserves, acquisitions, investment impairment charges, and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

	12M24
	As Reported (GAAP)		Specified Items		As Adjusted
Intangible Amortization	$        1,878		$      (1,878)		$              —
Gross Margin	21,366		2,213		23,579
R&D	2,844		(140)		2,704
SG&A	11,697		(117)		11,580
Other (income) expense, net	(376)		(163)		(539)
Earnings before taxes	7,013		2,633		9,646
Taxes on Earnings	(6,389)		7,835		1,446
Net Earnings	13,402		(5,202)		8,200
Diluted Earnings per Share	$         7.64		$        (2.97)		$         4.67

Specified items reflect intangible amortization expense of $1.878 billion and other net expenses of $755 million associated with intangible impairments, restructuring actions, acquisitions, a divestiture and other net expenses. See table titled "Details of Specified Items" for additional details regarding specified items.

A reconciliation of the fourth-quarter tax rates for 2025 and 2024 is shown below: 

	4Q25
($ in millions)	Pre-Tax Income		Taxes on Earnings		Tax Rate
As reported (GAAP)	$       2,358		$          582		24.7 %	1)
Specified items	728		(126)
Excluding specified items	$      3,086		$          456		14.8 %
	4Q24
($ in millions)	Pre-Tax Income		Taxes on Earnings		Tax Rate
As reported (GAAP)	$      2,030		$      (7,199)		(354.6 %)	2)
Specified items	733		7,613
Excluding specified items	$       2,763		$           414		15.0 %

1)	2025 Taxes on Earnings includes the recognition of approximately $20 million of net tax expense as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $150 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
2)	2024 Taxes on Earnings includes $7.497 billion in non-cash valuation allowance adjustments resulting from the restructuring of certain foreign affiliates and the confirmation of certain tax filing positions.

A reconciliation of the year-to-date tax rates for 2025 and 2024 is shown below: 

	12M25
($ in millions)	Pre-Tax Income		Taxes on Earnings		Tax Rate
As reported (GAAP)	$      8,466		$       1,942		22.9 %	3)
Specified items	2,296		(220)
Excluding specified items	$     10,762		$        1,722		16.0 %
	12M24
($ in millions)	Pre-Tax Income		Taxes on Earnings		Tax Rate
As reported (GAAP)	$       7,013		$     (6,389)		(91.1 %)	4)
Specified items	2,633		7,835
Excluding specified items	$      9,646		$       1,446		15.0 %

3)	2025 Taxes on Earnings includes the recognition of approximately $70 million of net tax benefit as a result of the resolution of various tax positions related to prior years. 2025 Taxes on Earnings also includes approximately $610 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.
4)	2024 Taxes on Earnings includes $7.497 billion in non-cash valuation allowance adjustments resulting from the restructuring of certain foreign affiliates and the confirmation of certain tax filing positions.

 

Abbott Laboratories and Subsidiaries Non-GAAP Revenue Reconciliation Twelve Months Ended December 31, 2025 and 2024 ($ in millions) (unaudited)
		12M25		12M24				% Change vs. 12M24
										Non-GAAP
		Abbott Reported		Abbott Reported	Impact from business exit (a)	Adjusted Revenue		Reported		Adjusted	Organic
Total Company		44,328		41,950	(13)	41,937		5.7		5.7	5.5
U.S.		17,126		16,323	(13)	16,310		4.9		5.0	5.0
Intl		27,202		25,627	—	25,627		6.1		6.1	5.9
Total Nutrition		8,451		8,413	(13)	8,400		0.4		0.5	1.2
U.S.		3,606		3,689	(13)	3,676		(2.3)		(1.9)	(1.9)
Intl		4,845		4,724	—	4,724		2.6		2.6	3.7
Adult Nutrition		4,477		4,390	(13)	4,377		2.0		2.3	3.0
U.S.		1,448		1,481	(13)	1,468		(2.2)		(1.4)	(1.4)
Intl		3,029		2,909	—	2,909		4.1		4.1	5.1

(a)	Reflects the impact of discontinuing the ZonePerfect® product line in the Nutrition business. This action was initiated in March 2024.

 

Abbott Laboratories and Subsidiaries Details of Specified Items Fourth Quarter Ended December 31, 2025 (in millions, except per share data) (unaudited)
	Acquisition or Divestiture- related (a)		Restructuring and Cost Reduction Initiatives (b)		Intangible Amortization		Other (c)		Total Specifieds
Gross Margin	$                    2		$                        3		$               422		$                    1		$              428
R&D	—		(14)		—		(15)		(29)
SG&A	(38)		(51)		—		(165)		(254)
Other (income) expense, net	(8)		(3)		—		(6)		(17)
Earnings before taxes	$                 48		$                      71		$               422		$                187		728
Taxes on Earnings (d)									(126)
Net Earnings									$              854
Diluted Earnings per Share									$             0.49

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)	Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)	Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.
c)	Other includes $165 million for legal reserves related to certain agreed-upon settlement. Other also includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products.
d)	Reflects the net tax benefit associated with the specified items and recognition of a tax expense as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $150 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

 

Abbott Laboratories and Subsidiaries Details of Specified Items Fourth Quarter Ended December 31, 2024 (in millions, except per share data) (unaudited)
	Acquisition or Divestiture- related (a)		Restructuring and Cost Reduction Initiatives (b)		Intangible Amortization		Other (c)		Total Specifieds
Gross Margin	$                  —		$                     49		$              465		$                159		$               673
R&D	(1)		(20)		—		(38)		(59)
SG&A	(5)		(22)		—		6		(21)
Other (income) expense, net	(2)		—		—		22		20
Earnings before taxes	$                   8		$                      91		$              465		$               169		733
Taxes on Earnings (d)									7,613
Net Earnings									$         (6,880)
Diluted Earnings per Share									$            (3.93)

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)	Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)	Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)	Other includes incremental costs to comply with the European Union's Medical Device Regulations (MDR) and In Vitro Diagnostics Medical Device Regulations (IVDR) requirements for previously approved products and intangible asset impairment charges.
d)	Reflects the net tax benefit associated with the specified items, including non-cash valuation allowance adjustments.

 

Abbott Laboratories and Subsidiaries Details of Specified Items Twelve Months Ended December 31, 2025 (in millions, except per share data) (unaudited)
	Acquisition or Divestiture- related (a)		Restructuring and Cost Reduction Initiatives (b)		Intangible Amortization		Other (c)		Total Specifieds
Gross Margin	$                   3		$                    128		$            1,682		$                   11		$            1,824
R&D	(1)		(56)		—		(55)		(112)
SG&A	(53)		(100)		—		(159)		(312)
Other (income) expense, net	(26)		(3)		—		(19)		(48)
Earnings before taxes	$                 83		$                   287		$            1,682		$              244		2,296
Taxes on Earnings (d)									(220)
Net Earnings									$            2,516
Diluted Earnings per Share									$              1.43

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)	Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)	Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans.
c)	Other includes $165 million for legal reserves related to certain agreed-upon settlement. Other also includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment impairments.
d)	Reflects the net tax benefit associated with the specified items and recognition of a tax benefit as a result of the resolution of various tax positions related to prior years. Taxes on Earnings includes approximately $610 million in adjustments related to prior recognition of a significant non-cash deferred tax benefit.

 

Abbott Laboratories and Subsidiaries Details of Specified Items Twelve Months Ended December 31, 2024 (in millions, except per share data) (unaudited)
	Acquisition or Divestiture- related (a)		Restructuring and Cost Reduction Initiatives (b)		Intangible Amortization		Other (c)		Total Specifieds
Gross Margin	$                    2		$                    125		$            1,878		$              208		$            2,213
R&D	(5)		(21)		—		(114)		(140)
SG&A	(37)		(39)		—		(41)		(117)
Other (income) expense, net	(155)		—		—		(8)		(163)
Earnings before taxes	$               199		$                    185		$            1,878		$                371		2,633
Taxes on Earnings (d)									7,835
Net Earnings									$         (5,202)
Diluted Earnings per Share									$            (2.97)

The table above provides additional details regarding the specified items described on table titled "Non-GAAP Reconciliation of Financial Information."
a)	Includes the loss on the sale of a non-core business.  Acquisition-related expenses include integration costs, which represent incremental costs directly related to integrating acquired businesses, as well as other costs related to business acquisitions.
b)	Restructuring and cost reduction initiative expenses include severance, outplacement and other direct costs associated with specific restructuring plans and cost reduction initiatives.
c)	Other includes incremental costs to comply with the MDR and IVDR regulations for previously approved products and charges for investment and intangible asset impairments.
d)	Reflects the net tax benefit associated with the specified items, including non-cash valuation allowance adjustments.

 

View original content:https://www.prnewswire.com/news-releases/abbott-reports-fourth-quarter-and-full-year-2025-results-issues-2026-financial-outlook-302668032.html

SOURCE Abbott

FAQ

What were Abbott (ABT) fourth-quarter 2025 adjusted diluted EPS?

Abbott reported 4Q25 adjusted diluted EPS $1.50, a 12% increase versus prior year.

What guidance did Abbott (ABT) give for full-year 2026 organic sales?

Abbott projects full-year 2026 organic sales growth of 6.5% to 7.5%.

What is Abbott's (ABT) 2026 adjusted diluted EPS outlook?

Abbott guides 2026 adjusted diluted EPS $5.55 to $5.80 (midpoint ≈ 10% growth).

When does Abbott (ABT) expect the Exact Sciences acquisition to close?

Abbott continues to expect the Exact Sciences transaction to close in Q2 2026.

How did Abbott's (ABT) Medical Devices and Nutrition segments perform in 4Q25?

Medical Devices sales rose 12.3% (reported) while Nutrition sales fell 8.9% (reported).

Did Abbott (ABT) report any recent regulatory approvals affecting devices?

Yes—Abbott reported FDA approval for the Volt PFA System and a CE Mark for TactiFlex Duo.

What dividend did Abbott (ABT) declare and when is it payable?

Abbott declared a quarterly dividend of $0.63 per share, payable Feb. 13, 2026 to shareholders of record Jan. 15, 2026.